JP4212892B2 - ベンゾフラン及びベンゾチオフェン誘導体 - Google Patents

ベンゾフラン及びベンゾチオフェン誘導体 Download PDF

Info

Publication number
JP4212892B2
JP4212892B2 JP2002547917A JP2002547917A JP4212892B2 JP 4212892 B2 JP4212892 B2 JP 4212892B2 JP 2002547917 A JP2002547917 A JP 2002547917A JP 2002547917 A JP2002547917 A JP 2002547917A JP 4212892 B2 JP4212892 B2 JP 4212892B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
methanesulfonyl
carbonitrile
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002547917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517088A (ja
JP2004517088A5 (https=
Inventor
マクラレン，ケビン・リー
スミス，デービッド・バーナード
トレイシー、ジャハーリ・ローラント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004517088A publication Critical patent/JP2004517088A/ja
Publication of JP2004517088A5 publication Critical patent/JP2004517088A5/ja
Application granted granted Critical
Publication of JP4212892B2 publication Critical patent/JP4212892B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002547917A 2000-12-05 2001-11-26 ベンゾフラン及びベンゾチオフェン誘導体 Expired - Fee Related JP4212892B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25128300P 2000-12-05 2000-12-05
PCT/EP2001/013716 WO2002046178A2 (en) 2000-12-05 2001-11-26 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors

Publications (3)

Publication Number Publication Date
JP2004517088A JP2004517088A (ja) 2004-06-10
JP2004517088A5 JP2004517088A5 (https=) 2005-12-22
JP4212892B2 true JP4212892B2 (ja) 2009-01-21

Family

ID=22951260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002547917A Expired - Fee Related JP4212892B2 (ja) 2000-12-05 2001-11-26 ベンゾフラン及びベンゾチオフェン誘導体

Country Status (16)

Country Link
US (1) US6433005B1 (https=)
EP (1) EP1347963B1 (https=)
JP (1) JP4212892B2 (https=)
KR (1) KR20030070054A (https=)
CN (1) CN1273460C (https=)
AR (1) AR035719A1 (https=)
AT (1) ATE274507T1 (https=)
AU (2) AU2002224890B2 (https=)
BR (1) BR0115963A (https=)
CA (1) CA2437048A1 (https=)
DE (1) DE60105195T2 (https=)
ES (1) ES2225641T3 (https=)
MX (1) MXPA03004398A (https=)
PT (1) PT1347963E (https=)
WO (1) WO2002046178A2 (https=)
ZA (1) ZA200303641B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (en) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
CA2409821A1 (en) * 2000-05-18 2002-11-18 Yoshikazu Ikeda Novel benzothiophene derivatives
EP1299377A2 (en) * 2000-06-28 2003-04-09 Eli Lilly And Company Spla2 inhibitors
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
CA2540289A1 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Substituted indole derivatives
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
WO2008055808A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
AU2011202542A1 (en) 2010-07-14 2012-02-02 Indian Institute Of Science Benzothiophene carboxamide compounds, composition and applications thereof
CN103819371B (zh) * 2012-11-16 2016-05-04 中国科学院大连化学物理研究所 一种对甲砜基苯甲醛的合成方法
CN103058988B (zh) * 2012-12-31 2015-09-02 中国人民大学 苯并噻吩及其衍生物及其制备方法与应用
CN110903225B (zh) * 2019-12-11 2021-11-09 苏州开元民生科技股份有限公司 一种对甲砜基苯甲醛的合成方法
CN114456136B (zh) * 2022-01-27 2024-06-07 广西中医药大学 双靶点非甾体抗炎化合物及其制备方法与用途
KR102542698B1 (ko) * 2022-04-05 2023-06-14 주식회사 베노바이오 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331854A (en) * 1964-12-14 1967-07-18 American Cyanamid Co Novel furan and thiophene compounds
US4745127A (en) * 1983-10-31 1988-05-17 Merck Frosst Canada, Inc. Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of leukotriene biosynthesis
US4933351A (en) 1983-10-31 1990-06-12 Merck Frosst Canada, Inc. Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
US4822803A (en) 1983-10-31 1989-04-18 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
DE3342624A1 (de) 1983-11-25 1984-03-29 Heinfried Dr. 4019 Monheim Grote Benzaronderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
US4621091A (en) 1984-10-09 1986-11-04 Merck & Co., Inc. 3-hydroxybenzo[b]thiophene-2-sulfide derivatives compositions, and method of use therefor
US5208253A (en) * 1992-02-24 1993-05-04 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo(b) thiophene-2-carboxamides as inhibitors of cell adhesion
WO1995002406A2 (en) 1993-07-15 1995-01-26 Warner-Lambert Company Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method
US5426113A (en) 1994-04-08 1995-06-20 Warner-Lambert Company Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5731342A (en) 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
PT791591E (pt) * 1996-02-22 2001-12-28 Lilly Co Eli Benzotiofenos, formulacoes que os contem e metodos

Also Published As

Publication number Publication date
JP2004517088A (ja) 2004-06-10
EP1347963B1 (en) 2004-08-25
DE60105195D1 (de) 2004-09-30
ZA200303641B (en) 2004-08-12
BR0115963A (pt) 2003-10-28
MXPA03004398A (es) 2003-09-05
AR035719A1 (es) 2004-07-07
CN1273460C (zh) 2006-09-06
ATE274507T1 (de) 2004-09-15
DE60105195T2 (de) 2005-09-08
US6433005B1 (en) 2002-08-13
CA2437048A1 (en) 2002-06-13
KR20030070054A (ko) 2003-08-27
CN1479736A (zh) 2004-03-03
ES2225641T3 (es) 2005-03-16
EP1347963A2 (en) 2003-10-01
AU2489002A (en) 2002-06-18
US20020107280A1 (en) 2002-08-08
WO2002046178A3 (en) 2002-10-10
WO2002046178A2 (en) 2002-06-13
AU2002224890B2 (en) 2007-03-22
PT1347963E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
JP4212892B2 (ja) ベンゾフラン及びベンゾチオフェン誘導体
JP4141954B2 (ja) Ｃｏｘｉｉインヒビターとしてのインドール誘導体
JP2003527368A (ja) Ｉｐアンタゴニストとしてのカルボン酸誘導体
AU2002224890A1 (en) Benzofuran and benzothiophene derivatives as selective COX-2 inhibitors
KR970011580B1 (ko) 항알레르기 활성을 갖는 신규의 벤조티오펜
KR100313180B1 (ko) 5-아로일나프탈렌 유도체
JP3942897B2 (ja) ｐ−（スルホニル）アリール及びヘテロアリール
US4910317A (en) Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
US4931459A (en) Method for treating acute respirator distress syndrome
US7049325B2 (en) Quinoline derivatives as anti-inflammatory agents
CN101296919A (zh) 苯并[b]噻吩衍生物极其制备方法
MXPA99006927A (en) 5-aroylnaphthalene derivatives
AU2002342722A1 (en) Indole derivatives as COX II inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081029

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees